Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Current Deferred Revenue for 11 consecutive years, with $9.4 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 83.61% year-over-year to $9.4 million; the TTM value through Mar 2026 reached $9.4 million, down 83.61%, while the annual FY2025 figure was $44.4 million, 32.64% down from the prior year.
  • Current Deferred Revenue hit $9.4 million in Q1 2026 for Wave Life Sciences, down from $44.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $150.1 million in Q4 2023 and bottomed at $9.4 million in Q1 2026.
  • Average Current Deferred Revenue over 5 years is $74.3 million, with a median of $57.3 million recorded in 2025.
  • Year-over-year, Current Deferred Revenue skyrocketed 375.5% in 2023 and then plummeted 83.61% in 2026.
  • Wave Life Sciences' Current Deferred Revenue stood at $31.6 million in 2022, then surged by 375.5% to $150.1 million in 2023, then crashed by 56.04% to $66.0 million in 2024, then crashed by 32.64% to $44.4 million in 2025, then crashed by 78.86% to $9.4 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $9.4 million, $44.4 million, and $46.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.